Dechra Veterinary Products

Vetoryl^® Capsules (trilostane)

For use in: Dogs only

Vetoryl Capsules are the only FDA approved pharmaceutical for the treatment of Pituitary-Dependent Hyperadrenocorticism (PDH) and Adrenal-Dependent Hyperadrenocorticism (ADH) in dogs.

Vetoryl Capsules contain trilostane, which selectively, and reversibly, inhibits the enzyme 3ß-hydroxysteroid dehydrogenase, which is involved in the synthesis of several steroids including cortisol and aldosterone.
At recommended dose rates, Vetoryl Capsules tend to have a more selective effect on glucocorticoid production, however the potential inhibition of aldosterone must always be borne in mind by the attending clinician.
Vetoryl Capsules reduce circulating cortisol levels, leading to improvement in many of the clinical signs of HAC.

Vetoryl Capsules provide flexible and accurate dosing with five strengths (5 mg, 10 mg, 30 mg, 60 mg and 120 mg capsules), helping to restore the dog's vitality by reducing the clinical signs associated with HAC.

Start Here

to recieve more information!

Important Safety Information
As with all drugs, side effects may occur. In field studies and post-approval experience, the most common side effects reported were: anorexia, lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without decreased sodium, elevated BUN, decreased Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insufficiency. In some cases, death has been reported as an outcome of these adverse events. Vetoryl Capsules are not for use in dogs with primary hepatic or renal disease, or in pregnant dogs.Refer to the prescribing information for complete details or visit www.dechra-us.com.

All personal information collected will be handled in accordance with Dechra's privacy policy, learn more here.